On January 5, 2022 Subsection 56(1) class exemption for practitioners to conduct activities with MDMA and psilocybin in relation to the Health Canada Special Access Program(SAP) came into force. The purpose of this exemption is to enable persons in charge of a hospital, hospital employees, practitioners and their agents, pharmacists, and licensed dealers to conduct necessary activities with MDMA and/or psilocybin that has been authorized for sale pursuant to subsection C.08.010(1) of the Food and Drug Regulation.
Download the PDF File for this Practice Support Tool:
Share this with friends, colleagues and team members:
